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Preclinical data have consistently suggested the pharmaceutical potential of kratom (Mitragyna
speciosa), including as a substitute therapy in opioid dependence. In this case report, we present
a case of a man with a long history of kratom use to help him cope with his opiate withdrawals
while abstaining from illicit drug use. This is the first published detailed case report highlighting
the potential use of kratom to aid opioid dependence encountered in the clinical setting. Our article
is also supported by literature review with regards to kratom’s safety profile and pharmacological
potential.
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INTRODUCTION
Polysubstance abuse and opioid dependence are
burgeoning issues stereotypically affecting the youths.
They are closely linked to social ill with spurring juvenile
crimes, hence risk public security due to the violent and
erratic behavior derived from the psychostimulants’
effects (Salas-Wright et al., 2017).
Clinical management of individuals with polysubstance
abuse, addiction and dependence is intricately
challenging as the program success highly depends on
the degree of self-awareness, their personal drive and
willingness to quit (Castine et al., 2019; Kennedy &
Gregoire, 2009). Pharmacological therapy may help to
an extent and to date, methadone is the most feasible and
the cheapest mode of substitution therapy adopted by
the Malaysian government as part of the harm reduction
policy to curb opioid dependence in the community
(Frank, 2020). Methadone is a synthetic opioid agonist
with affinity towards the endogenous mu-opioid
receptor with the preferential activation of β-arrestin
over the G-proteins, hence relieving opioid withdrawal
symptoms (Kapoor et al., 2020). The side effects, even
were mild and somatic, might be intolerable to some,
and this include excessive sweating, constipation and
dry mouth (Haber et al., 2017). In such cases, therapy
with other substitute therapy may be prescribed, such as
suboxone or buprenorphine, often at a much higher cost.
Kratom or Mitragyna speciosa is a plant homogenous to
the Southeast Asia with average range of the tree height
is between 13-52 feet (Khalid et al., 2021) (Figure 1). It
has dark green leaves and can grow up to 7 inches long
and 4 inches wide (Figure 2).

Figure 1. Kratom (Mitragyna speciosa) tree.

Figure 2. Kratom (Mitragyna speciosa) leaves.
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Recent years have witnessed promising results with
regards to kratom potential in mitigating opiate
dependence (Coe et al., 2019; Wilson et al., 2021; Wilson
et al., 2020). Kratom continues to garner attention in
view of its prolific potential. Small-scale clinical studies
have attempted to establish the pharmacokinetic, safety
profile and potential clinical use of kratom in humans
(Metastasio et al., 2020; Vicknasingam et al., 2020;
White, 2018). However, due to local and international
binding legislation, extensive trials were often dissuaded
and not given enough priority. In this case report, we
present a case of a man with opioid dependency who
successfully abstained from illicit drug use through selfadministration of kratom. This is the first case of its kind
highlighting the potential use of kratom to aid opioid
dependence encountered in the clinical setting.
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form made from dried kratom leaves, taken 2 spoonfuls
with mineral water, 3 times per day. Each dose would
last him for 4 to 5 hours before withdrawal symptom sets
in. He denied of tolerance symptoms and claimed to be
on the same dose throughout the years.
There were no significant changes in experience since
until the beginning of the year 2008, when he started
taking kratom in beverage form (Figure 3) bought from
the underground market, which he claimed to be more
accessible.

METHOD
Data collection was performed through a single session
of a one-to-one interview with the patient in May 2021.
The session took 55 to 60 minutes to complete and was
audio-recorded with written consent to ensure verbatim
transcription.
Literature review was performed through specified
keywords search using Boolean operators: ‘kratom’ OR
‘ketum’ AND ‘opioid’ OR ‘opiate’ AND ‘dependence’
OR ‘withdrawal’ from both Medline and Google Scholar
databases for articles published from the year 2000 to
date.
RESULTS
The case describes a man in his early 50s from northwest
Peninsular Malaysia. His first involvement with illicit
drug use began at the age of 24 in the year 1994 due
to peer influence and environmental pressure. He was
exposed to both heroin and cannabis, habitually taken
for recreational purposes. He was an intravenous drug
user (IVDU), injecting heroin 3-4 times per month, and
cannabis was regularly smoked in cigarettes. His typical
withdrawal symptoms from heroin include lethargy,
chills, feeling aloof and detached from the surroundings.
Over time, he developed tolerance, requiring more
frequent injection. Despite so, since supply was readily
available through peers, it did not affect his social
functioning. On the other hand, smoking cannabis was
habitual, and he was not dependent on it.
He decided to turn over a new leaf after he was eventually
caught and detained for drug abuse four years later and
spent some time in jail. Soon after his release, he was
determined to stop misusing illicit drugs, hence replacing
heroin with kratom to treat his heroin addiction. His
early kratom use in the year 2005 was in a powdered
E-ISSN 2477-0612

Figure 3. Kratom beverage
commonly sold in single-use
plastics.
He took 1 to 2 cups in the morning and another 2
cups at night. However, he had begun making his own
kratom beverage a little while later when supplies of
kratom leaves were easier to get. He was able to get
fresh kratom leaves sold at MYR 20 (less than $5) for
1 kilogram, which lasted for 10 days. He claimed the
same dosage was used throughout the years to reduce his
opioid withdrawal symptoms and addiction. His kratom
preparation was made pure, from boiling the leaves for
two hours straight (leaving the water from full to half
pot), giving it a mossy green color. The water was then
filtered for impurities and sediments, and was kept cool
before drinking. He was able to maintain his usual daily
activities with these 3 cups of self-prepared kratom
beverage daily, taken 1 cup every morning, afternoon,
and night. Throughout his kratom use, he completely
abstained from illicit drug use, including heroin.
His regular kratom use allows him to perform well
at work. He has had a stable office job and had even
received awards for excellent work performance
throughout his career, twice. However, he had enrolled
to the local methadone maintenance program in the
year 2021 in his effort to transition his kratom use to
methadone in view of the local legislation risk with
kratom. His baseline haematological and biochemical
data screened at the beginning of methadone programme
showed mild liver derangements: Haemoglobin: 15.3
d/dL, urea: 3.1 mmol/L, creatinine: 72 µmol/L, total
protein: 88 g/L, albumin: 36 g/L, alkaline phosphatase:
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117 U/L, aspartate aminotransferase: 270 U/L, alanine
aminotransferase: 241 U/L. In comparison, he felt that
methadone was technically easier to administer as it is
in the liquid form. He was started on 30 mg daily dose,
however, is currently still experiencing withdrawal
symptoms from kratom, hence was still on dose titration.
Methadone, according to him, causes incessant dry
mouth, hence he needed to chew gums regularly and
drink a lot of water.
Throughout his methadone program over the past two
months, the withdrawal symptoms from kratom were
described to be far worse than that experienced from
heroin. Among the symptoms described from kratom
withdrawal were crippling headache, body aches,
chills, sweatiness, watery eyes, and loss of appetite.
Furthermore, throughout the years of kratom use, he had
also noticed the development of skin hyperpigmentation
(Figure 4), dirty sclera, and dark circles under the
eyes, which, according to him, were pathognomonic
phenotypes associated with chronic kratom use.

Figure 4. Skin hyperpigmentation
is commonly associated with long
term kratom use (red arrows).
DISCUSSION
Our case exemplifies kratom potential to aid opiate
addiction and dependence. The use of kratom in
Malaysia in early 2005 was popular as a powdered form.
Fifty grams of the powder were sold at MYR5 (~$1),
whereas kratom as a beverage form was only introduced
beginning the year 2008. However, various kratom
concoctions admixed with harmful substances, such as
cough syrup and ashes from the mosquito coils were
fashioned to appeal the youngsters with more euphoric
effects, eventually giving its notorious name to this day
(Khalid et al., 2021).
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Kratom has been traditionally used for a wide range
of mild ailments, including diarrhea, fever, and pain
(Meireles et al., 2019), attributable to the biologically
active compounds found in its extract. The two main
alkaloid extracts from kratom that are of great interest
are the Mitragynine (MG) and the 7-hydroxymitragynine
(7-HMG) that are known to have high affinity towards
the mu-opioid receptors. Of the two, there are growing
evidence of MG having anti-depressant, anti-nociceptive,
anti-addiction, and anxiolytic effect (Meireles et al.,
2019). Furthermore, repeated doses with MG were not
found to result in opiate toxicity as seen with other opioids
such as morphine. This could be explained by the absence
of further receptor upregulation upon the saturation of
substrate-receptor bindings, even with increased dosing
(Kruegel et al., 2016; Váradi et al., 2016). Additionally,
MG is generally regarded as safe as there were variations
with regards to MG pharmacokinetics with the reported
Cmax of 423.68 ng/ml, 0.63 ug/ml, and 0.7 ug/ml at 20
mg/kg (de Moraes et al., 2009), 40 mg/kg (Janchawee
et al., 2007), and 50 mg/kg (Parthasarathy et al., 2010)
per oral dose with the corresponding Tmax of 1.26 hours,
1.83 hours, and 4.50 hours, respectively. This reflects
that the MG absorption is slow and minimal through oral
administration.
In contrast, 7-HMG is known to exert greater binding
affinity to mu-opioid receptor as compared to MG, hence
increased the risk for addiction, dependence (Hemby
et al., 2019 and tolerance to kratom (Matsumoto et al.,
2008). Chronic exposure to 7-HMG was also associated
with functional cognitive decline, including memory
deficit and reduced capacity for new learning (Hemby et
al., 2019). The presence of various alkaloids with diverse
biological effects in kratom warrant caution as kratom
beverage was harnessed from the leaves whole and
there was no exact and consistent quantification of the
different alkaloids present in the drink. Therefore, long
term capricious use of kratom may result in undesirable
effects that may eventually interrupt social functioning
(Hassan et al., 2019; Hemby et al., 2019).
In our case, the patient used kratom to aid heroin
withdrawal. The severity of heroin withdrawal is
contingent upon many factors including the average
intake, potency, and frequency of heroin use prior to
the attempt to quit or scale back. The severity of the
symptoms is commonly assessed through the Clinical
Opioid Withdrawal Scale (COWS) (Wallace & Papp,
2017) in the clinical setting. In such cases, the standard
medical procedure involves a thorough medical and
psychiatric assessment, followed by a supervised
medical detox program.
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Following a long history of kratom use to aid heroin
dependence, our patient eventually decided to enroll
in our methadone program in view of the constrictive
legislation with regards to kratom. According to available
literatures, kratom withdrawals have been treated with
buprenorphine-naloxone (Diep et al., 2018; Khazaeli
et al., 2018; Weiss & Douglas, 2021), benzodiazepines
(Sablaban & Gautam, 2020), and several other
symptom-triggered drugs including naltrexone,
dihydrocodeine, hydroxyzine (Stanciu et al., 2019) and
others with reportedly better treatment response than
methadone. Long term maintenance, however, needs to
be strategically planned to prevent future relapse.
Scientific efforts to translate preclinical studies involving
kratom use as a controlled medicine persistently lag due
to legal restrictions and vague policy. Furthermore, there
needs to be a consistent and reliable method to precisely
extract the various compounds within the kratom to
clearly distinguish and affirm its specific biological
property. Additionally, the alkaloid contents in the
kratom leaves differ according to the different stages of
maturity and the tree ecotype (Brown et al., 2017).
Despite the limitation of our study methodology of a
single descriptive case report, it was the first paper of its
kind highlighting the potential of kratom as a substitute
in the treatment of opioid dependence, despite the strong
literature going against its clinical use due to the risk
of addiction and other adverse health events (Corkery
et al., 2019; Matson & Schenk, 2019; Palasamudramet
al., 2019). We believe that judicial kratom use in clinical
research should be encouraged under strict regulation
and multiagency supervision to potentiate exploration of
kratom as a pharmacological option not only for opioid
addiction (Hemby et al., 2019), but also as anxiolytic
(Hemby et al., 2019), treatment modality for chronic
pain (Hemby et al., 2019), anti-cholesterol, and antidiabetes medication (Brown et al., 2017).
CONCLUSION
This case underscores the yet-to-be-explored kratom’s
potential to treat opioid dependence as substitution
therapy other than methadone, in humans. However,
given its foreseeable risk for abuse, proper monitoring
and careful dose titration in humans should be
pharmacologically tested and evaluated. Legislative
planning and interdisciplinary consensus with regards
to kratom use should be established to secure scientific
breakthroughs that would benefit healthcare, at the same
time taking public health and societal expectation into
consideration.
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